Literature DB >> 7670101

Chemokine regulation of human megakaryocytopoiesis.

A M Gewirtz1, J Zhang, J Ratajczak, M Ratajczak, K S Park, C Li, Z Yan, M Poncz.   

Abstract

We have previously shown that platelet factor 4 (PF4), a platelet-specific CXC chemokine, can directly and specifically inhibit human megakaryocyte colony formation. We therefore hypothesized that PF4 might function as a negative autocrine regulator of megakaryocytopoiesis. Herein we present additional studies characterizing the inhibitory effect of CXC chemokines on human megakaryocyte development. We first corroborated our initial studies by showing that recombinant human (rH) PF4, like the native protein, inhibited megakaryocytopoiesis. We then examined the inhibitory properties of other CXC family members. Neutrophil activating peptide-2 (NAP-2), a naturally occurring N-terminally cleaved beta TG peptide, was found to inhibit megakaryocytopoiesis with two to three orders of magnitude greater potency than PF4. Structure function studies showed that an N-terminal mutation, which eliminated NAP-2's neutrophil activating properties (NAP-2E2-->A), also abrogated its ability to inhibit megakaryocyte development. Further investigations of this type demonstrated that a chimeric PF4 protein (AELR/PF4) in which PF4's N-terminus was replaced with the first four amino acids of NAP-2 was also a potent inhibitor of megakaryocytopoiesis. Interleukin (IL)-8, another CXC chemokine, and three CC chemokines (macrophage inhibitory protein-1 alpha [MIP-1 alpha], MIP-1 beta, and C10) also specifically inhibited megakaryocyte colony formation at NAP-2 equivalent doses. CXC and CC chemokine inhibition was additive suggesting that the effects might be mediated through a common pathway. The inhibitory effects of NAP-2 and MIP-1 alpha could not be overcome by adding physiologically relevant amounts of recombinant human megakaryocyte growth and development factor (MGDR) (50 ng/mL) to the cultures. Using Northern blot and reverse transcriptase-polymerase chain reaction (RT-PCR) based analyses, we documented mRNA expression of IL-8 receptor isoforms alpha and beta in total platelet RNA and in normal human megakaryocytes, respectively. Based on these results, we hypothesize that chemokines play a physiologic role in regulating megakaryocytopoiesis. Because chemokines are elaborated by ancillary marrow cells, both autocrine and paracrine growth control is suggested, the effects of which might be exerted, in part, through alpha and beta IL-8 receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670101

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

1.  Monocyte-derived CXCL7 peptides in the marrow microenvironment.

Authors:  Manoj M Pillai; Mineo Iwata; Norihiro Awaya; Lynn Graf; Beverly Torok-Storb
Journal:  Blood       Date:  2006-01-03       Impact factor: 22.113

Review 2.  Megakaryocyte biology and related disorders.

Authors:  Liyan Pang; Mitchell J Weiss; Mortimer Poncz
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Authors:  Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles A N Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia A Libermann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-12       Impact factor: 11.205

Review 4.  Platelet-derived chemokines: pathophysiology and therapeutic aspects.

Authors:  Hans-Dieter Flad; Ernst Brandt
Journal:  Cell Mol Life Sci       Date:  2010-03-07       Impact factor: 9.261

5.  IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Authors:  Carolina Schinke; Orsolya Giricz; Weijuan Li; Aditi Shastri; Shanisha Gordon; Laura Barreyro; Laura Barreryo; Tushar Bhagat; Sanchari Bhattacharyya; Nandini Ramachandra; Matthias Bartenstein; Andrea Pellagatti; Jacqueline Boultwood; Amittha Wickrema; Yiting Yu; Britta Will; Sheng Wei; Ulrich Steidl; Amit Verma
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

6.  Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4.

Authors:  K Aneja; G Jalagadugula; G Mao; A Singh; A K Rao
Journal:  J Thromb Haemost       Date:  2011-02       Impact factor: 5.824

7.  The role of platelet factor 4 in radiation-induced thrombocytopenia.

Authors:  Michele P Lambert; Liqing Xiao; Yvonne Nguyen; M Anna Kowalska; Mortimer Poncz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-08-01       Impact factor: 7.038

8.  Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes.

Authors:  Michele P Lambert; Yuhuan Wang; Khalil H Bdeir; Yvonne Nguyen; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

9.  Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules.

Authors:  M P Lambert; R Meng; L Xiao; D C Harper; M S Marks; M A Kowalska; M Poncz
Journal:  J Thromb Haemost       Date:  2015-09-29       Impact factor: 5.824

10.  Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.

Authors:  Michele P Lambert; Lubica Rauova; Matthew Bailey; Martha C Sola-Visner; M Anna Kowalska; Mortimer Poncz
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.